#United States #financial results #Belgrade #Xtant Medical #CollagenX

Overview

Xtant Medical Holdings, Inc., a global leader in surgical solutions for spinal and orthopedic conditions, has recently announced its financial results for the third quarter of 2025. This report reveals significant growth and positive financial indicators that underline the company's commitment to innovation and operational efficiency.

Financial Performance Highlights

In Q3 2025, Xtant Medical reported total revenues of $33.3 million, marking a 19% increase year-over-year from $27.9 million reported in Q3 2024. This growth can largely be attributed to increased licensing revenue, which has bolstered the company's position in the medical technology sector.

The gross margin for this quarter reached 66.1%, up from 58.4% in the previous year. This improvement reflects a favorable sales mix and enhanced operational scale.

Notably, Xtant Medical achieved a net income of $1.3 million, a significant turnaround from a net loss of $5.0 million in Q3 2024. This positive shift in profitability showcases the effectiveness of the company’s strategic focus on cost management and product innovation.

Additionally, the adjusted EBITDA amounted to $4.5 million, a substantial contrast to the adjusted EBITDA loss of $1.0 million year-over-year. The operational cash flow brought in $4.6 million, compared to cash used in operations of $1.7 million in the same quarter last year.

Revenue Guidance and Future Outlook

Looking ahead, Xtant Medical is reiterating its full-year revenue guidance for FY25 to range between $131-$135 million, which equates to a growth of 11%-15% compared to FY24. This anticipated growth is set against the backdrop of the company’s strategic investments in product development and sales force expansion.

Strategic Developments

A key recent development is the pending sale of certain non-core assets, including the Coflex® and CoFix® products, and all international businesses to Companion Spine. This transaction is expected to close by the end of the year, allowing Xtant Medical to sharpen its focus on its core biologics business.

Innovative Product Launches

In alignment with its growth strategy, Xtant Medical launched CollagenX™, a new bovine collagen particulate product aimed at enhancing surgical wound closure. This product is designed to promote healing, prevent surgical site infections, and is adaptable across various surgical disciplines, expanding Xtant's operational capabilities in the healthcare market.

Sean Browne, President and CEO of Xtant Medical, emphasized the company’s focus on self-sustainability and the importance of the product launches. He noted that these initiatives are crucial in delivering accelerated revenue growth while judiciously managing expenses.

Financial Position

As of September 30, 2025, Xtant reported $10.6 million in cash and cash equivalents, an increase from $6.2 million as of December 31, 2024. The financial stability demonstrated in this quarter is pivotal as it indicates the company’s ability to invest in future opportunities while maintaining a robust operational framework.

Upcoming Conference Call

On November 11, 2025, Xtant Medical will host a webcast and conference call to discuss the third quarter financial results and provide insights into future strategies. Those interested can access the details on the company’s investor relations page.

Conclusion

Xtant Medical's third-quarter results highlight a pronounced trajectory of growth and sustainability. With strong revenue performance, innovative product launches, and a focused strategy, the company is well-positioned for future success. As it adapts to changing market conditions and consumer needs, Xtant illustrates a commitment to enhancing patient outcomes and delivering shareholder value.